Who
Laurent Fischer
Director
Company insider
Files Form 4 as: Director, AtaiBeckley; Director, Mirum Pharmaceuticals; CEO, President and Director, Adverum Biotechnologies; Director, ATAI Life Sciences; Director, Cti Biopharma; Chief Executive Officer, Tobira Therapeutics; Director, Panacos Pharmaceuticals.
In numbers
- Trades disclosed
- 123
- Buys
- 13
- Sells
- 3
- Bought
- $994K
- Sold
- $94K
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 25 Oct 2006
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,977 | filing |
| 29 May 2026filed 2 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,977 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,977 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,977 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —93,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code M | —150,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —120,000 | filing |
News
Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name Laurent Fischer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.